Get the Stockscreener App
4.99
3.48%
-0.18
Atara Biotherapeutics Inc stock is traded at $4.99, with a volume of 46,934.
It is down -3.48% in the last 24 hours and up +1.63% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
See More
Previous Close:
$5.17
Open:
$5
24h Volume:
46,934
Relative Volume:
0.12
Market Cap:
$40.81M
Revenue:
$120.77M
Net Income/Loss:
$32.69M
P/E Ratio:
1.7121
EPS:
2.9146
Net Cash Flow:
$-50.94M
1W Performance:
+5.94%
1M Performance:
+1.63%
6M Performance:
-65.54%
1Y Performance:
-18.60%
1-Day Range:
$4.87
$5.26
1-Week Range:
$4.30
$5.26
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
4.99 | 40.81M | 120.77M | 32.69M | -50.94M | 2.9146 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Atara Biotherapeutics, Inc. (ATRA) registers possible resale of 400K common shares tied to HCR warrant exercise - MSN
Securities Fraud Investigation Into Atara Biotherapeutics, Inc - natlawreview.com
ATRA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit - Lelezard
ATRA INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - Sahm
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ROSEN Counsel Encourages Atara Biotherapeutics Investors to Act - National Today
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
ATRA SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
ATRA Technical Analysis & Stock Price Forecast - Intellectia AI
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
ATRA STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics, Inc. (ATRA) Registers Possible Resale of 400K Common Shares Tied to HCR Warrant Exercise - Yahoo Finance
Aug Sectors: Is Atara Biotherapeutics Inc being accumulated by smart moneyWeekly Profit Report & Smart Investment Allocation Tips - baoquankhu1.vn
Deadline Alert: Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - The Norfolk Daily News
DEADLINE ALERT for LU, ATRA, and COTY: The Law Offices of - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara Biotherapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - Carroll County Mirror-Democrat
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Pomerantz Law Firm Announces the Filing of a Class Action Against Atara Biotherapeutics, Inc. and Certain OfficersATRA - PR Newswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Atara Biotherapeutics Faces Class Action Lawsuit - Intellectia AI
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors ... - Bluefield Daily Telegraph
Atara Biotherapeutics, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before May 22, 2026 to Discuss Your RightsATRA - marketscreener.com
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx - GlobeNewswire Inc.
2026-04-01 | ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! | NDAQ:ATRA | Press Release - Stockhouse
ATRA Stock Price, Quote & Chart | ATARA BIOTHERAPEUTICS INC (NASDAQ:ATRA) - ChartMill
Did You Lose Money Investing in Atara Biotherapeutics, - GlobeNewswire
Pomerantz Law Firm Files Class Action Against Atara Biotherapeutics - National Today
ATRA Investors Have Opportunity to Lead Atara Biotherapeutics Lawsuit - National Today
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Bluefield Daily Telegraph
Holzer & Holzer, LLC Reminds Investors of Lead Plaintiff - GlobeNewswire
Law Offices of Frank R. Cruz Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in - GuruFocus
ATRA Shareholder Alert: May 22, 2026 Lead Plaintiff Deadline in Atara Biotherapeutics, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Atara Biotherapeutic - natlawreview.com
Atara Biotherapeutics | 10-K: FY2025 Annual Report - Moomoo
Class Action Filed Against Atara Biotherapeutics, Inc. (ATRA) Seeking Recovery for Investors – Contact Levi & Korsinsky - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges Atara - globenewswire.com
ATRA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure ... - Black Hills Pioneer
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Bioth - GuruFocus
ATRA UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Atara Biotherapeutics (ATRA) Investors of Securities Class Action Deadline on May 22, 2026 - ChartMill
ROSEN, LEADING INVESTOR COUNSEL, Encourages Atara Biotherapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Law Offices of Howard G. Smith Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders To Inquire About Securities Fraud Class Action - ChartMill
Bragar Eagel & Squire, P.C. Announces that a Class Action - GlobeNewswire
ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara ... - Bluefield Daily Telegraph
ATRA Shareholder Alert: Investors With Losses May Seek to - GlobeNewswire
ATRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Atara Biotherapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ATRA Class Action ReminderRobbins LLP Reminds Investors - GlobeNewswire
Securities Fraud Investigation Into Atara Biotherapeutics, Inc. (ATRA) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm - The AI Journal
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant-Huerta Yanina | Chief Accounting Officer |
Mar 02 '26 |
Sale |
5.08 |
2,104 |
10,691 |
31,750 |
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
0.49%
1.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):